[Modelling the bronchial epithelium in chronic obstructive pulmonary disease using human induced pluripotential stem cells].

Modélisation de l’épithélium bronchique dans la bronchopneumopathie chronique obstructive par les cellules souches pluripotentes induites humaines.
Bronchial epithelium Bronchopneumopathie chronique obstructive Cellule souche pluripotente induite humaine Chronic obstructive pulmonary disease Différenciation dirigée Directed differentiation Human induced pluripotential stem cells Épithélium bronchique

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 12 01 2020
accepted: 12 01 2020
pubmed: 9 3 2020
medline: 21 10 2020
entrez: 9 3 2020
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease leading to irreversible destruction of the terminal bronchioles. Although the precise patho-physiological mechanisms remain to be elucidated, the bronchial epithelium seems to play a pivotal role in the disease. Recent studies have highlighted a great heterogeneity among COPD patients, with various disease courses including, in about half the cases, an origin in childhood. Modelling of COPD is a major goal but currently available models are imperfect. Our work aims to create a new in vitro cellular model to study the pathology of the disease. The differentiation of human induced pluripotential stem cells (hiPSCs) in bronchial epithelium is a step towards a better understanding of the developmental origin and the identification of new therapeutic targets.

Identifiants

pubmed: 32146059
pii: S0761-8425(20)30034-6
doi: 10.1016/j.rmr.2020.02.003
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

197-200

Informations de copyright

Copyright © 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

M Fieldès (M)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France. Electronic address: m_fieldes@hotmail.com.

E Ahmed (E)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France; Département de Pneumologie, CHU Montpellier, Montpellier, France.

C Bourguignon (C)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France.

J Mianné (J)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France.

C Vernisse (C)

PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France.

A Fort (A)

Département de Pneumologie, CHU Montpellier, Montpellier, France.

I Vachier (I)

Département de Pneumologie, CHU Montpellier, Montpellier, France.

A Bourdin (A)

Département de Pneumologie, CHU Montpellier, Montpellier, France; PhyMedExp, Université de Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France.

S Assou (S)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France.

J De Vos (J)

IRMB (Institut de Médecine Régénératrice et de Biothérapies de Montpellier), UMR 1183, CHU Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH